首页 > 最新文献

PLoS Medicine最新文献

英文 中文
Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment 患有或未患有神经系统疾病的 SARS-CoV-2/COVID-19 住院患者的长期疗效:三年随访评估
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-04-01 DOI: 10.1371/journal.pmed.1004263
Anna Eligulashvili, Moshe Gordon, Jimmy S Lee, Jeylin Lee, Shiv Mehrotra-Varma, Jai Mehrotra-Varma, Kevin Hsu, Imanyah Hilliard, Kristen Lee, Arleen Li, M. Essibayi, Judy Yee, D. Altschul, Emad Eskandar, M. Mehler, Tim Q Duong
Background Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes of patients with and without significant neurological manifestations during initial COVID-19 hospitalization. Methods and findings Patients hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection between 03/01/2020 and 4/16/2020 in the Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). This cohort consisted of 414 patients with COVID-19 with significant neurological manifestations and 1,199 propensity-matched patients (for age and COVID-19 severity score) with COVID-19 without neurological manifestations. Neurological involvement during the acute phase included acute stroke, new or recrudescent seizures, anatomic brain lesions, presence of altered mentation with evidence for impaired cognition or arousal, and neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal orientation and arousal signs). There were no significant group differences in female sex composition (44.93% versus 48.21%, p = 0.249), ICU and IMV status, white, not Hispanic (6.52% versus 7.84%, p = 0.380), and Hispanic (33.57% versus 38.20%, p = 0.093), except black non-Hispanic (42.51% versus 36.03%, p = 0.019). Primary outcomes were mortality, stroke, heart attack, major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. Secondary outcomes were neuroimaging findings (hemorrhage, active and prior stroke, mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), and volume loss). More patients in the neurological cohort were discharged to acute rehabilitation (10.39% versus 3.34%, p < 0.001) or skilled nursing facilities (35.75% versus 25.35%, p < 0.001) and fewer to home (50.24% versus 66.64%, p < 0.001) than matched controls. Incidence of readmission for any reason (65.70% versus 60.72%, p = 0.036), stroke (6.28% versus 2.34%, p < 0.001), and MACE (20.53% versus 16.51%, p = 0.032) was higher in the neurological cohort post-discharge. Per Kaplan–Meier univariate survival curve analysis, such patients in the neurological cohort were more likely to die post-discharge compared to controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; p < 0.001)). Across both cohorts, the major causes of death post-discharge were heart disease (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza and pneumonia (13.79%, 9.89%), COVID-19 (10.34%, 7.69%), and acute respiratory distress syndrome (ARDS) (10.34%, 6.59%). Factors associated with mortality after leaving the hospital involved the neurological cohort (odds ratio (OR): 1.802 (95% CI [1.2
背景 急性神经系统表现是急性冠状病毒病2019(COVID-19)的常见并发症。这项回顾性队列研究调查了在最初的COVID-19住院期间出现和未出现明显神经系统表现的患者的3年预后。研究方法和结果 纳入了 2020 年 1 月 3 日至 2020 年 4 月 16 日期间因感染严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)而在布朗克斯区蒙特菲奥里卫生系统(该地区是早期大流行的中心)住院治疗的患者。随访数据收集至 2023 年 1 月 23 日(COVID-19 后 3 年)。该队列包括 414 名有明显神经系统表现的 COVID-19 患者和 1199 名倾向匹配的无神经系统表现的 COVID-19 患者(根据年龄和 COVID-19 严重程度评分)。急性期的神经系统受累包括急性中风、新发或复发的癫痫发作、脑部解剖学病变、存在认知或唤醒受损证据的精神改变以及神经-COVID-19综合征(头痛、嗅觉障碍、老年性痴呆、化疗、眩晕、晕厥前兆、麻痹、颅神经异常、共济失调、自主神经功能障碍以及骨骼肌损伤,但定向力和唤醒体征正常)。在女性性别组成(44.93% 对 48.21%,P = 0.249)、ICU 和 IMV 状态、白人、非西班牙裔(6.52% 对 7.84%,P = 0.380)和西班牙裔(33.57% 对 38.20%,P = 0.093)方面,除黑人非西班牙裔(42.51% 对 36.03%,P = 0.019)外,没有明显的组间差异。主要结果为死亡率、中风、心脏病发作、主要不良心血管事件(MACE)、再感染和出院后再入院。次要结果是神经影像学检查结果(出血、活动性中风和既往中风、肿块效应、微出血、白质改变、微血管疾病(MVD)和容积损失)。与匹配的对照组相比,神经系统队列中更多的患者出院后去了急性康复中心(10.39% 对 3.34%,p < 0.001)或专业护理机构(35.75% 对 25.35%,p < 0.001),更少的患者出院后回家(50.24% 对 66.64%,p < 0.001)。出院后因任何原因再次入院(65.70% 对 60.72%,P = 0.036)、中风(6.28% 对 2.34%,P < 0.001)和 MACE(20.53% 对 16.51%,P = 0.032)的发生率在神经系统组群中更高。根据 Kaplan-Meier 单变量生存曲线分析,与对照组相比,神经系统队列中的此类患者出院后死亡的可能性更高(危险比:2.346,(95% 置信区间 (CI) [1.586, 3.470];p < 0.001))。在两个队列中,出院后死亡的主要原因是心脏病(神经系统13.79%,对照组15.38%)、败血症(8.63%,对照组17.58%)、流感和肺炎(13.79%,对照组9.89%)、COVID-19(10.34%,对照组7.69%)和急性呼吸窘迫综合征(ARDS)(10.34%,对照组6.59%)。与出院后死亡率相关的因素包括神经系统队列(几率比(OR):1.802(95% CI [1.237,2.608];P = 0.002))、出院处置(OR:1.508(95% CI [1.276,1.775];P < 0.001))、充血性心力衰竭(OR:2.281(95% CI [1.429,3.593];P < 0.001))、COVID-19 严重程度评分较高(OR:1.177(95% CI [1.062,1.304];P = 0.002))和年龄较大(OR:1.027(95% CI [1.010,1.044];P = 0.002))。除了神经系统组群的年龄调整后脑容量损失(p = 0.045)明显高于对照组之外,其他组群的放射学结果没有差异。该研究的患者队列仅限于第一波大流行期间感染 COVID-19 的患者,当时医院负担过重,疫苗尚未上市,治疗手段有限。在对后续疫情进行调查时,患者情况可能会有所不同。结论 与匹配的对照组相比,有神经系统表现的 COVID-19 患者的长期预后较差。这些发现提高了人们对密切监测和及时干预有神经系统表现的 COVID-19 患者的认识和需求,因为他们的病程包括最初的神经系统表现,与更高的发病率和死亡率相关。
{"title":"Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment","authors":"Anna Eligulashvili, Moshe Gordon, Jimmy S Lee, Jeylin Lee, Shiv Mehrotra-Varma, Jai Mehrotra-Varma, Kevin Hsu, Imanyah Hilliard, Kristen Lee, Arleen Li, M. Essibayi, Judy Yee, D. Altschul, Emad Eskandar, M. Mehler, Tim Q Duong","doi":"10.1371/journal.pmed.1004263","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004263","url":null,"abstract":"Background Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes of patients with and without significant neurological manifestations during initial COVID-19 hospitalization. Methods and findings Patients hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection between 03/01/2020 and 4/16/2020 in the Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). This cohort consisted of 414 patients with COVID-19 with significant neurological manifestations and 1,199 propensity-matched patients (for age and COVID-19 severity score) with COVID-19 without neurological manifestations. Neurological involvement during the acute phase included acute stroke, new or recrudescent seizures, anatomic brain lesions, presence of altered mentation with evidence for impaired cognition or arousal, and neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal orientation and arousal signs). There were no significant group differences in female sex composition (44.93% versus 48.21%, p = 0.249), ICU and IMV status, white, not Hispanic (6.52% versus 7.84%, p = 0.380), and Hispanic (33.57% versus 38.20%, p = 0.093), except black non-Hispanic (42.51% versus 36.03%, p = 0.019). Primary outcomes were mortality, stroke, heart attack, major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. Secondary outcomes were neuroimaging findings (hemorrhage, active and prior stroke, mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), and volume loss). More patients in the neurological cohort were discharged to acute rehabilitation (10.39% versus 3.34%, p < 0.001) or skilled nursing facilities (35.75% versus 25.35%, p < 0.001) and fewer to home (50.24% versus 66.64%, p < 0.001) than matched controls. Incidence of readmission for any reason (65.70% versus 60.72%, p = 0.036), stroke (6.28% versus 2.34%, p < 0.001), and MACE (20.53% versus 16.51%, p = 0.032) was higher in the neurological cohort post-discharge. Per Kaplan–Meier univariate survival curve analysis, such patients in the neurological cohort were more likely to die post-discharge compared to controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; p < 0.001)). Across both cohorts, the major causes of death post-discharge were heart disease (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza and pneumonia (13.79%, 9.89%), COVID-19 (10.34%, 7.69%), and acute respiratory distress syndrome (ARDS) (10.34%, 6.59%). Factors associated with mortality after leaving the hospital involved the neurological cohort (odds ratio (OR): 1.802 (95% CI [1.2","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of intravenous hyoscine butylbromide on slow progress in labor (BUSCLAB): A double-blind randomized placebo-controlled trial. 静脉注射丁溴酸东莨菪碱对产程进展缓慢的影响(BUSCLAB):双盲随机安慰剂对照试验。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-28 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004352
Lise Christine Gaudernack, Angeline Elisabeth Styve Einarsen, Ingvil Krarup Sørbye, Mirjam Lukasse, Nina Gunnes, Trond Melbye Michelsen

Background: Prolonged labor is a common condition associated with maternal and perinatal complications. The standard treatment with oxytocin for augmentation of labor increases the risk of adverse outcomes. Hyoscine butylbromide is a spasmolytic drug with few side effects shown to shorten labor when used in a general population of laboring women. However, research on its effect on preventing prolonged labor is lacking. We aimed to assess the effect of hyoscine butylbromide on the duration of labor in nulliparous women showing early signs of slow labor.

Methods and findings: In this double-blind randomized placebo-controlled trial, we included 249 nulliparous women at term with 1 fetus in cephalic presentation and spontaneous start of labor, showing early signs of prolonged labor by crossing the alert line of the World Health Organization (WHO) partograph. The trial was conducted at Oslo University Hospital in Norway from May 2019 to December 2021. One hundred and twenty-five participants were randomized to receive 1 ml hyoscine butylbromide (Buscopan) (20 mg/ml), while 124 received 1 ml sodium chloride intravenously. Randomization was computer-generated, with allocation concealment by opaque sequentially numbered sealed envelopes. The primary outcome was duration of labor from administration of the investigational medicinal product (IMP) to vaginal delivery, which was analyzed by Weibull regression to estimate the cause-specific hazard ratio (HR) of vaginal delivery between the 2 treatment groups, with associated 95% confidence interval (CI). A wide range of secondary maternal and perinatal outcomes were also evaluated. Time-to-event outcomes were analyzed by Weibull regression, whereas continuous and dichotomous outcomes were analyzed by median regression and logistic regression, respectively. All main analyses were based on the modified intention-to-treat (ITT) set of eligible women with signed informed consent receiving either of the 2 treatments. The follow-up period lasted during the postpartum hospital stay. All personnel, participants, and researchers were blinded to the treatment allocation. Median (mean) labor duration from IMP administration to vaginal delivery was 401 (440.8) min in the hyoscine butylbromide group versus 432.5 (453.6) min in the placebo group. We found no statistically significant association between IMP and duration of labor from IMP administration to vaginal delivery: cause-specific HR of 1.00 (95% CI [0.77, 1.29]; p = 0.993). Among 255 randomized women having received 1 dose of IMP, 169 women (66.3%) reported a mild adverse event: 75.2% in the hyoscine butylbromide group and 57.1% in the placebo group (Pearson's chi-square test: p = 0.002). More than half of eligible women were not included in the study because they did not wish to participate or were not included upon admission. The participants might have represented a selected group of women reducing the external validit

背景:产程延长是一种常见病,与产妇和围产期并发症有关。使用催产素催产的标准治疗方法会增加不良后果的风险。丁溴酸东莨菪碱是一种副作用小的解痉药物,在一般产妇中使用可缩短产程。然而,目前还缺乏对其预防产程延长效果的研究。我们的目的是评估丁溴酸东莨菪碱对出现早期慢产迹象的无阴道产妇产程的影响:在这项双盲随机安慰剂对照试验中,我们纳入了 249 名有 1 个头位胎儿、自然分娩开始的足月无痛分娩产妇,她们的早期产程超过了世界卫生组织(WHO)分娩图的警戒线,显示出产程延长的迹象。试验于2019年5月至2021年12月在挪威奥斯陆大学医院进行。125名参与者被随机分配接受1毫升东莨菪碱丁溴化物(Buscopan)(20毫克/毫升),124名参与者接受1毫升氯化钠静脉注射。随机化由计算机生成,并通过不透明的按顺序编号的密封信封进行分配隐藏。主要结果为从服用研究用药(IMP)到阴道分娩的产程时间,通过Weibull回归分析,估算出两个治疗组之间阴道分娩的特定原因危险比(HR),以及相关的95%置信区间(CI)。此外,还对一系列次要的孕产妇和围产期结果进行了评估。时间到事件的结果通过 Weibull 回归进行分析,而连续和二分结果则分别通过中位回归和逻辑回归进行分析。所有主要分析均基于修改后的意向性治疗(ITT)组,即签署知情同意书并接受两种治疗方法中任何一种的符合条件的妇女。随访期为产后住院期间。所有人员、参与者和研究人员对治疗分配均为盲人。从服用 IMP 到阴道分娩的中位(平均)产程时间为:东莨菪碱丁溴化物组 401 (440.8) 分钟,安慰剂组 432.5 (453.6) 分钟。我们发现,从服用 IMP 到阴道分娩,IMP 与分娩持续时间之间没有统计学意义上的显著关联:特定原因 HR 为 1.00(95% CI [0.77, 1.29];P = 0.993)。在 255 名随机接受了 1 剂 IMP 的产妇中,有 169 名产妇(66.3%)报告了轻度不良事件:丁溴酸东莨菪碱组为 75.2%,安慰剂组为 57.1%(皮尔森卡方检验:P = 0.002)。半数以上符合条件的妇女未被纳入研究,原因是她们不愿参与或入院时未被纳入。这些参与者可能是经过挑选的妇女群体,从而降低了研究的外部有效性:结论:在有产程延长风险的初产妇群体中,静脉注射一剂 20 毫克丁溴酸东莨菪碱在预防产程进展缓慢方面的效果并不优于安慰剂。要回答增加和/或重复服用丁溴酸东莨菪碱是否会对产程产生影响,还需要进一步研究:ClinicalTrials.gov (NCT03961165) EudraCT (2018-002338-19)。
{"title":"The effect of intravenous hyoscine butylbromide on slow progress in labor (BUSCLAB): A double-blind randomized placebo-controlled trial.","authors":"Lise Christine Gaudernack, Angeline Elisabeth Styve Einarsen, Ingvil Krarup Sørbye, Mirjam Lukasse, Nina Gunnes, Trond Melbye Michelsen","doi":"10.1371/journal.pmed.1004352","DOIUrl":"10.1371/journal.pmed.1004352","url":null,"abstract":"<p><strong>Background: </strong>Prolonged labor is a common condition associated with maternal and perinatal complications. The standard treatment with oxytocin for augmentation of labor increases the risk of adverse outcomes. Hyoscine butylbromide is a spasmolytic drug with few side effects shown to shorten labor when used in a general population of laboring women. However, research on its effect on preventing prolonged labor is lacking. We aimed to assess the effect of hyoscine butylbromide on the duration of labor in nulliparous women showing early signs of slow labor.</p><p><strong>Methods and findings: </strong>In this double-blind randomized placebo-controlled trial, we included 249 nulliparous women at term with 1 fetus in cephalic presentation and spontaneous start of labor, showing early signs of prolonged labor by crossing the alert line of the World Health Organization (WHO) partograph. The trial was conducted at Oslo University Hospital in Norway from May 2019 to December 2021. One hundred and twenty-five participants were randomized to receive 1 ml hyoscine butylbromide (Buscopan) (20 mg/ml), while 124 received 1 ml sodium chloride intravenously. Randomization was computer-generated, with allocation concealment by opaque sequentially numbered sealed envelopes. The primary outcome was duration of labor from administration of the investigational medicinal product (IMP) to vaginal delivery, which was analyzed by Weibull regression to estimate the cause-specific hazard ratio (HR) of vaginal delivery between the 2 treatment groups, with associated 95% confidence interval (CI). A wide range of secondary maternal and perinatal outcomes were also evaluated. Time-to-event outcomes were analyzed by Weibull regression, whereas continuous and dichotomous outcomes were analyzed by median regression and logistic regression, respectively. All main analyses were based on the modified intention-to-treat (ITT) set of eligible women with signed informed consent receiving either of the 2 treatments. The follow-up period lasted during the postpartum hospital stay. All personnel, participants, and researchers were blinded to the treatment allocation. Median (mean) labor duration from IMP administration to vaginal delivery was 401 (440.8) min in the hyoscine butylbromide group versus 432.5 (453.6) min in the placebo group. We found no statistically significant association between IMP and duration of labor from IMP administration to vaginal delivery: cause-specific HR of 1.00 (95% CI [0.77, 1.29]; p = 0.993). Among 255 randomized women having received 1 dose of IMP, 169 women (66.3%) reported a mild adverse event: 75.2% in the hyoscine butylbromide group and 57.1% in the placebo group (Pearson's chi-square test: p = 0.002). More than half of eligible women were not included in the study because they did not wish to participate or were not included upon admission. The participants might have represented a selected group of women reducing the external validit","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the UK soft drinks industry levy on health and health inequalities in children and adolescents in England: An interrupted time series analysis and population health modelling study. 英国软饮料行业征税对英格兰儿童和青少年健康及健康不平等的影响:间断时间序列分析和人口健康模型研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-28 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004371
Linda J Cobiac, Nina T Rogers, Jean Adams, Steven Cummins, Richard Smith, Oliver Mytton, Martin White, Peter Scarborough

Background: The soft drinks industry levy (SDIL) in the United Kingdom has led to a significant reduction in household purchasing of sugar in drinks. In this study, we examined the potential medium- and long-term implications for health and health inequalities among children and adolescents in England.

Methods and findings: We conducted a controlled interrupted time series analysis to measure the effects of the SDIL on the amount of sugar per household per week from soft drinks purchased, 19 months post implementation and by index of multiple deprivation (IMD) quintile in England. We modelled the effect of observed sugar reduction on body mass index (BMI), dental caries, and quality-adjusted life years (QALYs) in children and adolescents (0 to 17 years) by IMD quintile over the first 10 years following announcement (March 2016) and implementation (April 2018) of the SDIL. Using a lifetable model, we simulated the potential long-term impact of these changes on life expectancy for the current birth cohort and, using regression models with results from the IMD-specific lifetable models, we calculated the impact of the SDIL on the slope index of inequality (SII) in life expectancy. The SDIL was found to have reduced sugar from purchased drinks in England by 15 g/household/week (95% confidence interval: -10.3 to -19.7). The model predicts these reductions in sugar will lead to 3,600 (95% uncertainty interval: 946 to 6,330) fewer dental caries and 64,100 (54,400 to 73,400) fewer children and adolescents classified as overweight or obese, in the first 10 years after implementation. The changes in sugar purchasing and predicted impacts on health are largest for children and adolescents in the most deprived areas (Q1: 11,000 QALYs [8,370 to 14,100] and Q2: 7,760 QALYs [5,730 to 9,970]), while children and adolescents in less deprived areas will likely experience much smaller simulated effects (Q3: -1,830 QALYs [-3,260 to -501], Q4: 652 QALYs [-336 to 1,680], Q5: 1,860 QALYs [929 to 2,890]). If the simulated effects of the SDIL are sustained over the life course, it is predicted there will be a small but significant reduction in slope index of inequality: 0.76% (95% uncertainty interval: -0.9 to -0.62) for females and 0.94% (-1.1 to -0.76) for males.

Conclusions: We predict that the SDIL will lead to medium-term reductions in dental caries and overweight/obesity, and long-term improvements in life expectancy, with the greatest benefits projected for children and adolescents from more deprived areas. This study provides evidence that the SDIL could narrow health inequalities for children and adolescents in England.

背景:英国软饮料行业征税(SDIL)导致家庭购买含糖饮料的数量大幅减少。在本研究中,我们探讨了这一措施对英格兰儿童和青少年的健康和健康不平等的潜在中长期影响:我们进行了一项受控间断时间序列分析,以衡量《特殊和差别待遇清单》在实施 19 个月后对英格兰每个家庭每周从软饮料中购买的糖量的影响,并按多重贫困指数 (IMD) 五分位数进行了分析。我们模拟了在 SDIL 宣布(2016 年 3 月)和实施(2018 年 4 月)后的前 10 年中,观察到的糖分减少对儿童和青少年(0 至 17 岁)体重指数 (BMI)、龋齿和质量调整生命年 (QALY) 的影响,并按 IMD 五分位数进行了分类。利用生命表模型,我们模拟了这些变化对当前出生组群预期寿命的潜在长期影响,并利用 IMD 特定生命表模型结果的回归模型,计算了 SDIL 对预期寿命不平等斜率指数 (SII) 的影响。结果发现,在英格兰,"特殊和差别化生活指数 "使每户每周从购买的饮料中摄入的糖分减少了 15 克(95% 置信区间:-10.3 到 -19.7)。该模型预测,在实施后的头 10 年中,这些糖分的减少将导致龋齿减少 3,600 例(95% 置信区间:946 至 6,330 例),被归类为超重或肥胖的儿童和青少年减少 64,100 例(54,400 至 73,400 例)。对于最贫困地区的儿童和青少年而言,购买食糖的变化和对健康的预测影响最大(第一季度:11,000 QALYs [8,370 至 14,100] ;第二季度:7,760 QALYs [8,370 至 14,100] ):7,760 QALYs [5,730 至 9,970] ),而较贫困地区的儿童和青少年受到的模拟影响可能要小得多(Q3:-1,830 QALYs [-3,260 至 -501],Q4:652 QALYs [-336 至 1,680] ,Q5:1,860 QALYs [929 至 2,890])。如果 SDIL 的模拟效果在整个生命过程中得以持续,预计不平等斜率指数将有小幅但显著的下降:女性下降 0.76%(95% 不确定区间:-0.9 至 -0.62),男性下降 0.94%(-1.1 至 -0.76):我们预测,SDIL 将导致龋齿和超重/肥胖的中期减少以及预期寿命的长期改善,预计来自更贫困地区的儿童和青少年将受益最大。这项研究提供的证据表明,英格兰儿童和青少年特殊营养需求计划可以缩小健康方面的不平等。
{"title":"Impact of the UK soft drinks industry levy on health and health inequalities in children and adolescents in England: An interrupted time series analysis and population health modelling study.","authors":"Linda J Cobiac, Nina T Rogers, Jean Adams, Steven Cummins, Richard Smith, Oliver Mytton, Martin White, Peter Scarborough","doi":"10.1371/journal.pmed.1004371","DOIUrl":"10.1371/journal.pmed.1004371","url":null,"abstract":"<p><strong>Background: </strong>The soft drinks industry levy (SDIL) in the United Kingdom has led to a significant reduction in household purchasing of sugar in drinks. In this study, we examined the potential medium- and long-term implications for health and health inequalities among children and adolescents in England.</p><p><strong>Methods and findings: </strong>We conducted a controlled interrupted time series analysis to measure the effects of the SDIL on the amount of sugar per household per week from soft drinks purchased, 19 months post implementation and by index of multiple deprivation (IMD) quintile in England. We modelled the effect of observed sugar reduction on body mass index (BMI), dental caries, and quality-adjusted life years (QALYs) in children and adolescents (0 to 17 years) by IMD quintile over the first 10 years following announcement (March 2016) and implementation (April 2018) of the SDIL. Using a lifetable model, we simulated the potential long-term impact of these changes on life expectancy for the current birth cohort and, using regression models with results from the IMD-specific lifetable models, we calculated the impact of the SDIL on the slope index of inequality (SII) in life expectancy. The SDIL was found to have reduced sugar from purchased drinks in England by 15 g/household/week (95% confidence interval: -10.3 to -19.7). The model predicts these reductions in sugar will lead to 3,600 (95% uncertainty interval: 946 to 6,330) fewer dental caries and 64,100 (54,400 to 73,400) fewer children and adolescents classified as overweight or obese, in the first 10 years after implementation. The changes in sugar purchasing and predicted impacts on health are largest for children and adolescents in the most deprived areas (Q1: 11,000 QALYs [8,370 to 14,100] and Q2: 7,760 QALYs [5,730 to 9,970]), while children and adolescents in less deprived areas will likely experience much smaller simulated effects (Q3: -1,830 QALYs [-3,260 to -501], Q4: 652 QALYs [-336 to 1,680], Q5: 1,860 QALYs [929 to 2,890]). If the simulated effects of the SDIL are sustained over the life course, it is predicted there will be a small but significant reduction in slope index of inequality: 0.76% (95% uncertainty interval: -0.9 to -0.62) for females and 0.94% (-1.1 to -0.76) for males.</p><p><strong>Conclusions: </strong>We predict that the SDIL will lead to medium-term reductions in dental caries and overweight/obesity, and long-term improvements in life expectancy, with the greatest benefits projected for children and adolescents from more deprived areas. This study provides evidence that the SDIL could narrow health inequalities for children and adolescents in England.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The bidirectional association between premenstrual disorders and perinatal depression: A nationwide register-based study from Sweden. 经前期紊乱与围产期抑郁之间的双向关联:瑞典的一项全国性登记研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-28 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004363
Qian Yang, Emma Bränn, Elizabeth R Bertone-Johnson, Arvid Sjölander, Fang Fang, Anna Sara Oberg, Unnur A Valdimarsdóttir, Donghao Lu

Background: Premenstrual disorders (PMDs) and perinatal depression (PND) share symptomology and the timing of symptoms of both conditions coincide with natural hormonal fluctuations, which may indicate a shared etiology. Yet, there is a notable absence of prospective data on the potential bidirectional association between these conditions, which is crucial for guiding clinical management. Using the Swedish nationwide registers with prospectively collected data, we aimed to investigate the bidirectional association between PMDs and PND.

Methods and findings: With 1,803,309 singleton pregnancies of 1,041,419 women recorded in the Swedish Medical Birth Register during 2001 to 2018, we conducted a nested case-control study to examine the risk of PND following PMDs, which is equivalent to a cohort study, and transitioned that design into a matched cohort study with onward follow-up to simulate a prospective study design and examine the risk of PMDs after PND (within the same study population). Incident PND and PMDs were identified through clinical diagnoses or prescribed medications. We randomly selected 10 pregnant women without PND, individually matched to each PND case on maternal age and calendar year using incidence density sampling (N: 84,949: 849,482). We (1) calculated odds ratio (OR) and 95% confidence intervals (CIs) of PMDs using conditional logistic regression in the nested case-control study. Demographic factors (country of birth, educational level, region of residency, and cohabitation status) were adjusted for. We (2) calculated the hazard ratio (HR) and 95% CIs of PMDs subsequent to PND using stratified Cox regression in the matched cohort study. Smoking, BMI, parity, and history of psychiatric disorders were further controlled for, in addition to demographic factors. Pregnancies from full sisters of PND cases were identified for sibling comparison, which contrasts the risk within each set of full sisters discordant on PND. In the nested case-control study, we identified 2,488 PMDs (2.9%) before pregnancy among women with PND and 5,199 (0.6%) among controls. PMDs were associated with a higher risk of subsequent PND (OR 4.76, 95% CI [4.52,5.01]; p < 0.001). In the matched cohort with a mean follow-up of 7.40 years, we identified 4,227 newly diagnosed PMDs among women with PND (incidence rate (IR) 7.6/1,000 person-years) and 21,326 among controls (IR 3.8). Compared to their matched controls, women with PND were at higher risk of subsequent PMDs (HR 1.81, 95% CI [1.74,1.88]; p < 0.001). The bidirectional association was noted for both prenatal and postnatal depression and was stronger among women without history of psychiatric disorders (p for interaction < 0.001). Sibling comparison showed somewhat attenuated, yet statistically significant, bidirectional associations. The main limitation of this study was that our findings, based on clinical diagnoses recorded in registers, may not generalize we

背景:经前期紊乱(PMDs)和围产期抑郁症(PND)具有共同的症状,而且这两种疾病的症状出现时间与自然的荷尔蒙波动相吻合,这可能表明它们具有共同的病因。然而,关于这两种疾病之间潜在的双向联系的前瞻性数据却明显缺乏,而这种联系对于指导临床治疗至关重要。我们利用瑞典全国范围内的前瞻性登记数据,旨在研究 PMD 与 PND 之间的双向关联:2001年至2018年期间,瑞典出生医学登记册记录了1,041,419名妇女的1,803,309次单胎妊娠,我们开展了一项巢式病例对照研究,以考察PMD后发生PND的风险,这相当于一项队列研究,并将该设计过渡为一项具有后续随访的匹配队列研究,以模拟前瞻性研究设计,考察PND后发生PMD的风险(在同一研究人群中)。通过临床诊断或处方药来确定是否发生 PND 和 PMD。我们随机抽取了 10 名未患有 PND 的孕妇,通过发病密度抽样(N:84,949:849,482)与每个 PND 病例的孕产妇年龄和日历年单独匹配。我们(1)在巢式病例对照研究中使用条件逻辑回归法计算了PMD的几率比(OR)和95%置信区间(CI)。对人口统计学因素(出生国、教育程度、居住地区和同居状况)进行了调整。我们(2)在配对队列研究中使用分层考克斯回归法计算了PND后PMD的危险比(HR)和95% CIs。除人口统计学因素外,我们还进一步控制了吸烟、体重指数、胎次和精神病史。为进行同胞比较,确定了 PND 病例全姐妹的怀孕情况,从而对比了每组 PND 不一致的全姐妹的风险。在巢式病例对照研究中,我们在PND女性患者中发现了2488例(2.9%)孕前PMD,在对照组中发现了5199例(0.6%)。PMD与随后发生PND的较高风险相关(OR 4.76,95% CI [4.52,5.01];P < 0.001)。在平均随访7.40年的匹配队列中,我们在患有PND的妇女中发现了4227例新诊断的PMD(发病率(IR)为7.6/1,000人年),在对照组中发现了21326例新诊断的PMD(IR为3.8)。与匹配的对照组相比,罹患PND的妇女随后罹患PMD的风险更高(HR 1.81,95% CI [1.74,1.88];P < 0.001)。产前和产后抑郁均存在双向关联,在无精神病史的妇女中,这种关联性更强(交互作用 p < 0.001)。同胞比较显示的双向关联有所减弱,但在统计学上有显著意义。本研究的主要局限性在于,我们的研究结果是基于登记册中记录的临床诊断,可能无法很好地推广到患有轻度 PMD 或 PND 的妇女:在这项研究中,我们观察到 PMD 与 PND 之间存在双向关联。这些研究结果表明,PMD病史可为PND易感性提供信息,反之亦然,并为这两种疾病之间的共同病因提供了支持。
{"title":"The bidirectional association between premenstrual disorders and perinatal depression: A nationwide register-based study from Sweden.","authors":"Qian Yang, Emma Bränn, Elizabeth R Bertone-Johnson, Arvid Sjölander, Fang Fang, Anna Sara Oberg, Unnur A Valdimarsdóttir, Donghao Lu","doi":"10.1371/journal.pmed.1004363","DOIUrl":"10.1371/journal.pmed.1004363","url":null,"abstract":"<p><strong>Background: </strong>Premenstrual disorders (PMDs) and perinatal depression (PND) share symptomology and the timing of symptoms of both conditions coincide with natural hormonal fluctuations, which may indicate a shared etiology. Yet, there is a notable absence of prospective data on the potential bidirectional association between these conditions, which is crucial for guiding clinical management. Using the Swedish nationwide registers with prospectively collected data, we aimed to investigate the bidirectional association between PMDs and PND.</p><p><strong>Methods and findings: </strong>With 1,803,309 singleton pregnancies of 1,041,419 women recorded in the Swedish Medical Birth Register during 2001 to 2018, we conducted a nested case-control study to examine the risk of PND following PMDs, which is equivalent to a cohort study, and transitioned that design into a matched cohort study with onward follow-up to simulate a prospective study design and examine the risk of PMDs after PND (within the same study population). Incident PND and PMDs were identified through clinical diagnoses or prescribed medications. We randomly selected 10 pregnant women without PND, individually matched to each PND case on maternal age and calendar year using incidence density sampling (N: 84,949: 849,482). We (1) calculated odds ratio (OR) and 95% confidence intervals (CIs) of PMDs using conditional logistic regression in the nested case-control study. Demographic factors (country of birth, educational level, region of residency, and cohabitation status) were adjusted for. We (2) calculated the hazard ratio (HR) and 95% CIs of PMDs subsequent to PND using stratified Cox regression in the matched cohort study. Smoking, BMI, parity, and history of psychiatric disorders were further controlled for, in addition to demographic factors. Pregnancies from full sisters of PND cases were identified for sibling comparison, which contrasts the risk within each set of full sisters discordant on PND. In the nested case-control study, we identified 2,488 PMDs (2.9%) before pregnancy among women with PND and 5,199 (0.6%) among controls. PMDs were associated with a higher risk of subsequent PND (OR 4.76, 95% CI [4.52,5.01]; p < 0.001). In the matched cohort with a mean follow-up of 7.40 years, we identified 4,227 newly diagnosed PMDs among women with PND (incidence rate (IR) 7.6/1,000 person-years) and 21,326 among controls (IR 3.8). Compared to their matched controls, women with PND were at higher risk of subsequent PMDs (HR 1.81, 95% CI [1.74,1.88]; p < 0.001). The bidirectional association was noted for both prenatal and postnatal depression and was stronger among women without history of psychiatric disorders (p for interaction < 0.001). Sibling comparison showed somewhat attenuated, yet statistically significant, bidirectional associations. The main limitation of this study was that our findings, based on clinical diagnoses recorded in registers, may not generalize we","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10978009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of oncogenic HPV infection in women with and without mental illness: A population-based cohort study in Sweden. 患有和未患有精神疾病的女性中致癌型 HPV 感染的发生率:瑞典一项基于人群的队列研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-25 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004372
Eva Herweijer, Kejia Hu, Jiangrong Wang, Donghao Lu, Pär Sparén, Hans-Olov Adami, Unnur Valdimarsdóttir, Karin Sundström, Fang Fang

Background: Women with mental illness experience an increased risk of cervical cancer. The excess risk is partly due to low participation in cervical screening; however, it remains unknown whether it is also attributable to an increased risk of infection with human papillomavirus (HPV). We aimed to examine whether women with mental illness had an increased infection rate of HPV compared to women without mental illness.

Methods and findings: Using a cohort design, we analyzed all 337,116 women aged 30 to 64 and living in Stockholm, who had a negative test result of 14 high-risk HPV subtypes in HPV-based screening, during August 2014 to December 2019. We defined women as exposed to mental illness if they had a specialist diagnosis of mental disorder or had a filled prescription of psychotropic medication. We identified incident infection of any high-risk HPV during follow-up and fitted multivariable Cox models to estimate hazard ratios (HR) with 95% confidence intervals (CI) for HPV infection. A total of 3,263 women were tested positive for high-risk HPV during follow-up (median: 2.21 years; range: 0 to 5.42 years). The absolute infection rate of HPV was higher among women with a specialist diagnosis of mental disorder (HR = 1.45; 95% CI [1.34, 1.57]; p < 0.001) or a filled prescription of psychotropic medication (HR = 1.67; 95% CI [1.55, 1.79]; p < 0.001), compared to women without such. The increment in absolute infection rate was noted for depression, anxiety, stress-related disorder, substance-related disorder, and ADHD, and for use of antidepressants, anxiolytics, sedatives, and hypnotics, and was consistent across age groups. The main limitations included selection of the female population in Stockholm as they must have at least 1 negative test result of HPV, and relatively short follow-up as HPV-based screening was only introduced in 2014 in Stockholm.

Conclusions: Mental illness is associated with an increased infection rate of high-risk HPV in women. Our findings motivate refined approaches to facilitate the WHO elimination agenda of cervical cancer among these marginalized women worldwide.

背景:患有精神疾病的女性罹患宫颈癌的风险会增加。宫颈癌风险增加的部分原因是宫颈癌筛查参与率低,但是否与感染人类乳头瘤病毒(HPV)的风险增加有关,目前仍不得而知。我们旨在研究与没有精神疾病的女性相比,患有精神疾病的女性感染人乳头瘤病毒的比例是否会增加:我们采用队列设计,分析了所有 337116 名年龄在 30 至 64 岁、居住在斯德哥尔摩的女性,她们在 2014 年 8 月至 2019 年 12 月期间进行的基于 HPV 的筛查中,14 种高风险 HPV 亚型的检测结果均为阴性。如果妇女经专科医生诊断患有精神障碍或开具了精神药物处方,我们就将其定义为暴露于精神疾病。我们确定了随访期间感染任何高危 HPV 的事件,并通过多变量 Cox 模型估算出 HPV 感染的危险比 (HR) 及 95% 置信区间 (CI)。在随访期间(中位数:2.21 年;范围:0 至 5.42 年),共有 3263 名妇女的高危 HPV 检测结果呈阳性。与无精神障碍的妇女相比,有精神障碍专科诊断(HR = 1.45;95% CI [1.34,1.57];p < 0.001)或精神药物处方(HR = 1.67;95% CI [1.55,1.79];p < 0.001)的妇女的 HPV 绝对感染率更高。抑郁症、焦虑症、压力相关障碍、药物相关障碍和多动症,以及使用抗抑郁药、抗焦虑药、镇静剂和催眠药的绝对感染率均有所上升,且各年龄组的情况一致。研究的主要局限性包括对斯德哥尔摩女性人群的选择,因为她们必须至少有一次人乳头瘤病毒阴性检测结果;以及随访时间相对较短,因为斯德哥尔摩在2014年才引入基于人乳头瘤病毒的筛查:结论:精神疾病与女性高危 HPV 感染率的增加有关。我们的研究结果促使我们改进方法,以促进世界卫生组织在全球这些边缘化妇女中消除宫颈癌的议程。
{"title":"Incidence of oncogenic HPV infection in women with and without mental illness: A population-based cohort study in Sweden.","authors":"Eva Herweijer, Kejia Hu, Jiangrong Wang, Donghao Lu, Pär Sparén, Hans-Olov Adami, Unnur Valdimarsdóttir, Karin Sundström, Fang Fang","doi":"10.1371/journal.pmed.1004372","DOIUrl":"10.1371/journal.pmed.1004372","url":null,"abstract":"<p><strong>Background: </strong>Women with mental illness experience an increased risk of cervical cancer. The excess risk is partly due to low participation in cervical screening; however, it remains unknown whether it is also attributable to an increased risk of infection with human papillomavirus (HPV). We aimed to examine whether women with mental illness had an increased infection rate of HPV compared to women without mental illness.</p><p><strong>Methods and findings: </strong>Using a cohort design, we analyzed all 337,116 women aged 30 to 64 and living in Stockholm, who had a negative test result of 14 high-risk HPV subtypes in HPV-based screening, during August 2014 to December 2019. We defined women as exposed to mental illness if they had a specialist diagnosis of mental disorder or had a filled prescription of psychotropic medication. We identified incident infection of any high-risk HPV during follow-up and fitted multivariable Cox models to estimate hazard ratios (HR) with 95% confidence intervals (CI) for HPV infection. A total of 3,263 women were tested positive for high-risk HPV during follow-up (median: 2.21 years; range: 0 to 5.42 years). The absolute infection rate of HPV was higher among women with a specialist diagnosis of mental disorder (HR = 1.45; 95% CI [1.34, 1.57]; p < 0.001) or a filled prescription of psychotropic medication (HR = 1.67; 95% CI [1.55, 1.79]; p < 0.001), compared to women without such. The increment in absolute infection rate was noted for depression, anxiety, stress-related disorder, substance-related disorder, and ADHD, and for use of antidepressants, anxiolytics, sedatives, and hypnotics, and was consistent across age groups. The main limitations included selection of the female population in Stockholm as they must have at least 1 negative test result of HPV, and relatively short follow-up as HPV-based screening was only introduced in 2014 in Stockholm.</p><p><strong>Conclusions: </strong>Mental illness is associated with an increased infection rate of high-risk HPV in women. Our findings motivate refined approaches to facilitate the WHO elimination agenda of cervical cancer among these marginalized women worldwide.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Clinical outcomes in a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: A cohort analysis using routine data. 更正:约旦叙利亚难民和东道国人口非传染性疾病初级计划的临床结果:利用常规数据进行的队列分析。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-22 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004373
Éimhín Ansbro, Tobias Homan, David Prieto Merino, Kiran Jobanputra, Jamil Qasem, Shoaib Muhammad, Taissir Fardous, Pablo Perel

[This corrects the article DOI: 10.1371/journal.pmed.1003279.].

[此处更正了文章 DOI:10.1371/journal.pmed.1003279]。
{"title":"Correction: Clinical outcomes in a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: A cohort analysis using routine data.","authors":"Éimhín Ansbro, Tobias Homan, David Prieto Merino, Kiran Jobanputra, Jamil Qasem, Shoaib Muhammad, Taissir Fardous, Pablo Perel","doi":"10.1371/journal.pmed.1004373","DOIUrl":"10.1371/journal.pmed.1004373","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1371/journal.pmed.1003279.].</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data. 量化巴西结核病治疗过程中的差距:利用国家项目数据进行数学模型研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-21 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004361
Sivaram Emani, Kleydson Alves, Layana Costa Alves, Daiane Alves da Silva, Patricia Bartholomay Oliveira, Marcia C Castro, Ted Cohen, Rodrigo de Macedo Couto, Mauro Sanchez, Nicolas A Menzies

Background: In Brazil, many individuals with tuberculosis (TB) do not receive appropriate care due to delayed or missed diagnosis, ineffective treatment regimens, or loss-to-follow-up. This study aimed to estimate the health losses and TB program costs attributable to each gap in the care cascade for TB disease in Brazil.

Methods and findings: We constructed a Markov model simulating the TB care cascade and lifetime health outcomes (e.g., death, cure, postinfectious sequelae) for individuals developing TB disease in Brazil. We stratified the model by age, human immunodeficiency virus (HIV) status, drug resistance, state of residence, and disease severity, and developed a parallel model for individuals without TB that receive a false-positive TB diagnosis. Models were fit to data (adult and pediatric) from Brazil's Notifiable Diseases Information System (SINAN) and Mortality Information System (SIM) for 2018. Using these models, we assessed current program performance and simulated hypothetical scenarios that eliminated specific gaps in the care cascade, in order to quantify incremental health losses and TB diagnosis and treatment costs along the care cascade. TB-attributable disability-adjusted life years (DALYs) were calculated by comparing changes in survival and nonfatal disability to a no-TB counterfactual scenario. We estimated that 90.0% (95% uncertainty interval [UI]: 85.2 to 93.4) of individuals with TB disease initiated treatment and 10.0% (95% UI: 7.6 to 12.5) died with TB. The average number of TB-attributable DALYs per incident TB case varied across Brazil, ranging from 2.9 (95% UI: 2.3 to 3.6) DALYs in Acre to 4.0 (95% UI: 3.3 to 4.7) DALYs in Rio Grande do Sul (national average 3.5 [95% UI: 2.8 to 4.1]). Delayed diagnosis contributed the largest health losses along the care cascade, followed by post-TB sequelae and loss to follow up from TB treatment, with TB DALYs reduced by 71% (95% UI: 65 to 76), 41% (95% UI: 36 to 49), and 10% (95% UI: 7 to 16), respectively, when these factors were eliminated. Total health system costs were largely unaffected by improvements in the care cascade, with elimination of treatment failure reducing attributable costs by 3.1% (95% UI: 1.5 to 5.4). TB diagnosis and treatment of false-positive individuals accounted for 10.2% (95% UI: 3.9 to 21.7) of total programmatic costs but contributed minimally to health losses. Several assumptions were required to interpret programmatic data for the analysis, and we were unable to estimate the contribution of social factors to care cascade outcomes.

Conclusions: In this study, we observed that delays to diagnosis, post-disease sequelae and treatment loss to follow-up were primary contributors to the TB burden of disease in Brazil. Reducing delays to diagnosis, improving healthcare after TB cure, and reducing treatment loss to follow-up should be prioritized to improve the burden of TB disease in Braz

背景:在巴西,许多结核病患者由于诊断延误或漏诊、治疗方案无效或失去随访而得不到适当的治疗。本研究旨在估算巴西结核病治疗过程中的每一个缺口所造成的健康损失和结核病项目成本:我们构建了一个马尔可夫模型,模拟巴西结核病患者的治疗过程和终生健康结果(如死亡、治愈、感染后遗症)。我们按照年龄、人类免疫缺陷病毒(HIV)感染状况、耐药性、居住州和疾病严重程度对模型进行了分层,并为获得假阳性肺结核诊断的非肺结核患者开发了一个平行模型。模型与 2018 年巴西应报疾病信息系统(SINAN)和死亡率信息系统(SIM)的数据(成人和儿童)进行了拟合。利用这些模型,我们评估了当前的项目绩效,并模拟了消除护理级联中特定差距的假设情景,以量化护理级联中的增量健康损失和结核病诊断与治疗成本。通过比较存活率和非致死性残疾与无结核病反事实情景的变化,计算出结核病导致的残疾调整生命年(DALYs)。我们估计,90.0%(95% 不确定区间 [UI]:85.2-93.4)的结核病患者开始接受治疗,10.0%(95% 不确定区间 [UI]:7.6-12.5)的患者死于结核病。在巴西各地,每例肺结核病例造成的可归因于肺结核的残疾调整寿命年数各不相同,从阿克里州的 2.9(95% UI:2.3 至 3.6)个残疾调整寿命年数到南里奥格兰德州的 4.0(95% UI:3.3 至 4.7)个残疾调整寿命年数不等(全国平均为 3.5 [95% UI:2.8 至 4.1])。在整个治疗过程中,延误诊断造成的健康损失最大,其次是结核病后遗症和结核病治疗后的随访损失,如果剔除这些因素,结核病的残疾调整寿命年数将分别减少 71%(95% UI:65 至 76)、41%(95% UI:36 至 49)和 10%(95% UI:7 至 16)。医疗系统的总成本基本未受治疗流程改进的影响,而治疗失败因素的消除则使可归因成本降低了 3.1%(95% UI:1.5 至 5.4)。对假阳性患者的结核病诊断和治疗占项目总成本的 10.2%(95% UI:3.9 至 21.7),但对健康损失的影响微乎其微。为了对项目数据进行分析,我们需要做出一些假设,而且我们无法估计社会因素对治疗结果的影响:在这项研究中,我们注意到诊断延误、疾病后遗症和随访治疗损失是造成巴西结核病负担的主要原因。为改善巴西的结核病负担,应优先考虑减少诊断延误、改善结核病治愈后的医疗保健以及减少治疗后的随访损失。
{"title":"Quantifying gaps in the tuberculosis care cascade in Brazil: A mathematical model study using national program data.","authors":"Sivaram Emani, Kleydson Alves, Layana Costa Alves, Daiane Alves da Silva, Patricia Bartholomay Oliveira, Marcia C Castro, Ted Cohen, Rodrigo de Macedo Couto, Mauro Sanchez, Nicolas A Menzies","doi":"10.1371/journal.pmed.1004361","DOIUrl":"10.1371/journal.pmed.1004361","url":null,"abstract":"<p><strong>Background: </strong>In Brazil, many individuals with tuberculosis (TB) do not receive appropriate care due to delayed or missed diagnosis, ineffective treatment regimens, or loss-to-follow-up. This study aimed to estimate the health losses and TB program costs attributable to each gap in the care cascade for TB disease in Brazil.</p><p><strong>Methods and findings: </strong>We constructed a Markov model simulating the TB care cascade and lifetime health outcomes (e.g., death, cure, postinfectious sequelae) for individuals developing TB disease in Brazil. We stratified the model by age, human immunodeficiency virus (HIV) status, drug resistance, state of residence, and disease severity, and developed a parallel model for individuals without TB that receive a false-positive TB diagnosis. Models were fit to data (adult and pediatric) from Brazil's Notifiable Diseases Information System (SINAN) and Mortality Information System (SIM) for 2018. Using these models, we assessed current program performance and simulated hypothetical scenarios that eliminated specific gaps in the care cascade, in order to quantify incremental health losses and TB diagnosis and treatment costs along the care cascade. TB-attributable disability-adjusted life years (DALYs) were calculated by comparing changes in survival and nonfatal disability to a no-TB counterfactual scenario. We estimated that 90.0% (95% uncertainty interval [UI]: 85.2 to 93.4) of individuals with TB disease initiated treatment and 10.0% (95% UI: 7.6 to 12.5) died with TB. The average number of TB-attributable DALYs per incident TB case varied across Brazil, ranging from 2.9 (95% UI: 2.3 to 3.6) DALYs in Acre to 4.0 (95% UI: 3.3 to 4.7) DALYs in Rio Grande do Sul (national average 3.5 [95% UI: 2.8 to 4.1]). Delayed diagnosis contributed the largest health losses along the care cascade, followed by post-TB sequelae and loss to follow up from TB treatment, with TB DALYs reduced by 71% (95% UI: 65 to 76), 41% (95% UI: 36 to 49), and 10% (95% UI: 7 to 16), respectively, when these factors were eliminated. Total health system costs were largely unaffected by improvements in the care cascade, with elimination of treatment failure reducing attributable costs by 3.1% (95% UI: 1.5 to 5.4). TB diagnosis and treatment of false-positive individuals accounted for 10.2% (95% UI: 3.9 to 21.7) of total programmatic costs but contributed minimally to health losses. Several assumptions were required to interpret programmatic data for the analysis, and we were unable to estimate the contribution of social factors to care cascade outcomes.</p><p><strong>Conclusions: </strong>In this study, we observed that delays to diagnosis, post-disease sequelae and treatment loss to follow-up were primary contributors to the TB burden of disease in Brazil. Reducing delays to diagnosis, improving healthcare after TB cure, and reducing treatment loss to follow-up should be prioritized to improve the burden of TB disease in Braz","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10994550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial. 更正:尼日利亚索科托治疗无并发症严重急性营养不良的每月随访计划的效果:分组随机交叉试验。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-20 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004370
Matt D T Hitchings, Fatou Berthé, Philip Aruna, Ibrahim Shehu, Muhammed Ali Hamza, Siméon Nanama, Chizoba Steve-Edemba, Rebecca F Grais, Sheila Isanaka

[This corrects the article DOI: 10.1371/journal.pmed.1003923.].

[此处更正了文章 DOI:10.1371/journal.pmed.1003923]。
{"title":"Correction: Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial.","authors":"Matt D T Hitchings, Fatou Berthé, Philip Aruna, Ibrahim Shehu, Muhammed Ali Hamza, Siméon Nanama, Chizoba Steve-Edemba, Rebecca F Grais, Sheila Isanaka","doi":"10.1371/journal.pmed.1004370","DOIUrl":"10.1371/journal.pmed.1004370","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1371/journal.pmed.1003923.].</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Socioeconomic position indicators and risk of alcohol-related medical conditions: A national cohort study from Sweden. 社会经济地位指标与酒精相关疾病的风险:瑞典全国队列研究。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-19 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004359
Alexis C Edwards, Sara Larsson Lönn, Karen G Chartier, Séverine Lannoy, Jan Sundquist, Kenneth S Kendler, Kristina Sundquist

Background: Alcohol consumption contributes to excess morbidity and mortality in part through the development of alcohol-related medical conditions (AMCs, including alcoholic cardiomyopathy, hepatitis, cirrhosis, etc.). The current study aimed to clarify the extent to which risk for these outcomes differs as a function of socioeconomic position (SEP), as discrepancies could lead to exacerbated health disparities.

Methods and findings: We used longitudinal Swedish national registries to estimate the individual and joint associations between 2 SEP indicators, educational attainment and income level, and risk of AMC based on International Classification of Diseases codes, while controlling for other sociodemographic covariates and psychiatric illness. We conducted Cox proportional hazards models in sex-stratified analyses (N = 1,162,679 females and N = 1,196,659 males), beginning observation at age 40 with follow-up through December 2018, death, or emigration. By the end of follow-up, 4,253 (0.37%) females and 11,183 (0.93%) males had received an AMC registration, corresponding to overall AMC incidence rates among females and males of 2.01 and 5.20, respectively. In sex-stratified models adjusted for birth year, marital status, region of origin, internalizing and externalizing disorder registrations, and alcohol use disorder (AUD) registration, lower educational attainment was associated with higher risk of AMC in both females (hazard ratios [HRs] = 1.40 to 2.46 for low- and mid-level educational attainment across 0 to 15 years of observation) and males (HRs = 1.13 to 1.48). Likewise, risk of AMC was increased for those with lower income levels (females: HRs = 1.10 to 5.86; males: HRs = 1.07 to 6.41). In secondary analyses, we further adjusted for aggregate familial risk of AUD by including family genetic risk scores for AUD (FGRSAUD), estimated using medical, pharmacy, and criminal registries in extended families, as covariates. While FGRSAUD were associated with risk of AMC in adjusted models (HR = 1.17 for females and HR = 1.21 for males), estimates for education and income level remained largely unchanged. Furthermore, FGRSAUD interacted with income level, but not education level, such that those at higher familial liability to AUD were more susceptible to the adverse effect of low income. Limitations of these analyses include the possibility of false negatives for psychiatric illness registrations, changes in income after age 40 that were not accounted for due to modeling restrictions, restriction to residents of a high-income country, and the inability to account for individual-level alcohol consumption using registry data.

Conclusions: Using comprehensive national registry data, these analyses demonstrate that individuals with lower levels of education and/or income are at higher risk of developing AMC. These associations persist even when accounting for a range of sociodemogra

背景:饮酒导致发病率和死亡率过高,部分原因是酒精相关疾病(AMC,包括酒精性心肌病、肝炎、肝硬化等)的发生。本研究旨在阐明这些结果的风险在多大程度上与社会经济地位(SEP)有关,因为两者之间的差异可能会导致健康差异的加剧:我们利用瑞典国家纵向登记资料,根据国际疾病分类编码,估算了教育程度和收入水平这两个社会经济地位指标与 AMC 风险之间的个体关联和联合关联,同时控制了其他社会人口协变量和精神疾病。我们在性别分层分析(女性人数=1,162,679 人,男性人数=1,196,659 人)中采用了 Cox 比例危险模型,从 40 岁开始观察,随访至 2018 年 12 月、死亡或移民。在随访结束时,有4253名女性(0.37%)和11183名男性(0.93%)接受了AMC登记,对应的女性和男性总体AMC发病率分别为2.01和5.20。在根据出生年份、婚姻状况、原籍地区、内化和外化障碍注册情况以及酒精使用障碍(AUD)注册情况进行调整的性别分层模型中,教育程度较低的女性(在0至15年的观察期间,教育程度较低和教育程度中等的女性的危险比[HRs] = 1.40至2.46)和男性(HRs = 1.13至1.48)罹患AMC的风险都较高。同样,收入水平较低的人群罹患 AMC 的风险也会增加(女性:HRs = 1.10 至 5.86;男性:HRs = 1.07 至 6.41)。在二次分析中,我们将利用大家庭的医疗、药房和犯罪登记估算出的 AUD 家族遗传风险评分 (FGRSAUD) 作为协变量,进一步调整了 AUD 的家族总体风险。虽然在调整模型中,FGRSAUD 与 AMC 风险相关(女性 HR = 1.17,男性 HR = 1.21),但教育程度和收入水平的估计值基本保持不变。此外,FGRSAUD 与收入水平交互作用,但与教育水平无关,因此,那些对 AUD 有较高家族责任的人更容易受到低收入的不利影响。这些分析的局限性包括:精神疾病登记可能出现假阴性;由于建模限制,40 岁以后的收入变化没有考虑在内;仅限于高收入国家的居民;无法利用登记数据考虑个人层面的酒精消费:这些分析利用全面的国家登记数据证明,教育和/或收入水平较低的人罹患 AMC 的风险较高。即使考虑到一系列社会人口、精神和家庭风险因素,这些关联仍然存在。风险差异可能会进一步加剧健康差距,因此有必要在临床和公共卫生环境中加大筛查和预防力度。
{"title":"Socioeconomic position indicators and risk of alcohol-related medical conditions: A national cohort study from Sweden.","authors":"Alexis C Edwards, Sara Larsson Lönn, Karen G Chartier, Séverine Lannoy, Jan Sundquist, Kenneth S Kendler, Kristina Sundquist","doi":"10.1371/journal.pmed.1004359","DOIUrl":"https://doi.org/10.1371/journal.pmed.1004359","url":null,"abstract":"<p><strong>Background: </strong>Alcohol consumption contributes to excess morbidity and mortality in part through the development of alcohol-related medical conditions (AMCs, including alcoholic cardiomyopathy, hepatitis, cirrhosis, etc.). The current study aimed to clarify the extent to which risk for these outcomes differs as a function of socioeconomic position (SEP), as discrepancies could lead to exacerbated health disparities.</p><p><strong>Methods and findings: </strong>We used longitudinal Swedish national registries to estimate the individual and joint associations between 2 SEP indicators, educational attainment and income level, and risk of AMC based on International Classification of Diseases codes, while controlling for other sociodemographic covariates and psychiatric illness. We conducted Cox proportional hazards models in sex-stratified analyses (N = 1,162,679 females and N = 1,196,659 males), beginning observation at age 40 with follow-up through December 2018, death, or emigration. By the end of follow-up, 4,253 (0.37%) females and 11,183 (0.93%) males had received an AMC registration, corresponding to overall AMC incidence rates among females and males of 2.01 and 5.20, respectively. In sex-stratified models adjusted for birth year, marital status, region of origin, internalizing and externalizing disorder registrations, and alcohol use disorder (AUD) registration, lower educational attainment was associated with higher risk of AMC in both females (hazard ratios [HRs] = 1.40 to 2.46 for low- and mid-level educational attainment across 0 to 15 years of observation) and males (HRs = 1.13 to 1.48). Likewise, risk of AMC was increased for those with lower income levels (females: HRs = 1.10 to 5.86; males: HRs = 1.07 to 6.41). In secondary analyses, we further adjusted for aggregate familial risk of AUD by including family genetic risk scores for AUD (FGRSAUD), estimated using medical, pharmacy, and criminal registries in extended families, as covariates. While FGRSAUD were associated with risk of AMC in adjusted models (HR = 1.17 for females and HR = 1.21 for males), estimates for education and income level remained largely unchanged. Furthermore, FGRSAUD interacted with income level, but not education level, such that those at higher familial liability to AUD were more susceptible to the adverse effect of low income. Limitations of these analyses include the possibility of false negatives for psychiatric illness registrations, changes in income after age 40 that were not accounted for due to modeling restrictions, restriction to residents of a high-income country, and the inability to account for individual-level alcohol consumption using registry data.</p><p><strong>Conclusions: </strong>Using comprehensive national registry data, these analyses demonstrate that individuals with lower levels of education and/or income are at higher risk of developing AMC. These associations persist even when accounting for a range of sociodemogra","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. C 亚型 ALVAC-HIV (vCP2438) 疫苗原种加用 MF59 或明矾佐剂的二价 C 亚型 gp120 增效疫苗在未感染 HIV 的健康成人中的安全性和免疫原性(HVTN 107):1/2a期随机试验。
IF 15.8 1区 医学 Q1 Medicine Pub Date : 2024-03-19 eCollection Date: 2024-03-01 DOI: 10.1371/journal.pmed.1004360
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert
<p><strong>Background: </strong>Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen modified for the Southern African region. The RV144 trial of a recombinant canarypox vaccine vector expressing HIV env subtype B (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost adjuvanted with alum is the only trial to have shown modest HIV vaccine efficacy. Data generated after RV144 suggested that use of MF59 adjuvant might allow lower protein doses to be used while maintaining robust immune responses. We evaluated safety and immunogenicity of an HIV recombinant canarypox vaccine vector expressing HIV env subtype C (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost (gp120) adjuvanted with alum (ALVAC-HIV+gp120/alum) or MF59 (ALVAC-HIV+gp120/MF59) or unadjuvanted (ALVAC-HIV+gp120/no-adjuvant) and a regimen where ALVAC-HIV+gp120 adjuvanted with MF59 was used for the prime and boost (ALVAC-HIV+gp120/MF59 coadministration).</p><p><strong>Methods and findings: </strong>Between June 19, 2017 and June 14, 2018, 132 healthy adults without HIV in South Africa, Zimbabwe, and Mozambique were randomized to receive intramuscularly: (1) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/MF59 (months 3, 6, and 12), n = 36; (2) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/alum (months 3, 6, and 12), n = 36; (3) 4 doses of ALVAC-HIV+gp120/MF59 coadministered (months 0, 1, 6, and 12), n = 36; or (4) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/no adjuvant (months 3, 6, and 12), n = 24. Primary outcomes were safety and occurrence and mean fluorescence intensity (MFI) of vaccine-induced gp120-specific IgG and IgA binding antibodies at month 6.5. All vaccinations were safe and well-tolerated; increased alanine aminotransferase was the most frequent related adverse event, occurring in 2 (1.5%) participants (1 severe, 1 mild). At month 6.5, vaccine-specific gp120 IgG binding antibodies were detected in 100% of vaccinees for all 4 vaccine groups. No significant differences were seen in the occurrence and net MFI of vaccine-specific IgA responses between the ALVAC-HIV+gp120/MF59-prime-boost and ALVAC-HIV+gp120/alum-prime-boost groups or between the ALVAC-HIV+gp120/MF59-prime-boost and ALVAC-HIV+gp120/MF59 coadministration groups. Limitations were the relatively small sample size per group and lack of evaluation of higher gp120 doses.</p><p><strong>Conclusions: </strong>Although MF59 was expected to enhance immune responses, alum induced similar responses to MF59, suggesting that the choice between these adjuvants may not be critical for the ALVAC+gp120 regimen.</p><p><strong>Trial registration: </s
背景:佐剂被广泛用于增强和/或引导疫苗诱导的免疫反应,但很少进行头对头的评估。我们的试验直接比较了在针对南部非洲地区改良的 RV144 类 HIV 疫苗方案中,MF59 佐剂与明矾佐剂所引起的免疫反应。在 RV144 试验中,先接种表达 B 亚型 HIV env 的重组加那利痘疫苗载体(ALVAC-HIV),然后接种 ALVAC-HIV 加用明矾佐剂的二价 gp120 蛋白疫苗增强剂,这是唯一显示出适度 HIV 疫苗效力的试验。RV144 试验后获得的数据表明,使用 MF59 佐剂可以降低蛋白剂量,同时维持强大的免疫反应。我们评估了表达 HIV env C 亚型的 HIV 重组加那利痘疫苗载体(ALVAC-HIV)原体的安全性和免疫原性,然后评估了 ALVAC-HIV 加用明矾佐剂的二价 gp120 蛋白疫苗增强剂(gp120)(ALVAC-HIV+gp120/明矾)的安全性和免疫原性。HIV+gp120/明矾)或 MF59(ALVAC-HIV+gp120/MF59)佐剂或无佐剂(ALVAC-HIV+gp120/无佐剂)佐剂,以及将 ALVAC-HIV+gp120 与 MF59 佐剂用于前体和加强体的方案(ALVAC-HIV+gp120/MF59 联合给药)。方法和结果:2017年6月19日至2018年6月14日期间,南非、津巴布韦和莫桑比克的132名未感染艾滋病毒的健康成年人随机接受了肌肉注射:(1) 2剂ALVAC-HIV(第0和第1个月),然后是3剂ALVAC-HIV+gp120/MF59(第3、6和12个月),n = 36;(2) 2剂ALVAC-HIV(第0和第1个月),然后是3剂ALVAC-HIV+gp120/alum(第3、6和12个月),n = 36;(3) 联合给药 4 次 ALVAC-HIV+gp120/MF59(第 0、1、6 和 12 个月),n = 36;或 (4) 给药 2 次 ALVAC-HIV(第 0 和 1 个月),然后给药 3 次 ALVAC-HIV+gp120/无辅助剂(第 3、6 和 12 个月),n = 24。主要结果是安全性以及第 6.5 个月时疫苗诱导的 gp120 特异性 IgG 和 IgA 结合抗体的发生率和平均荧光强度 (MFI)。所有疫苗接种均安全且耐受性良好;丙氨酸氨基转移酶升高是最常见的相关不良事件,有 2 名参与者(1.5%)发生(1 例重度,1 例轻度)。第 6.5 个月时,在所有 4 个疫苗组中,100% 的接种者都检测到了疫苗特异性 gp120 IgG 结合抗体。在ALVAC-HIV+gp120/MF59-prime-boost组和ALVAC-HIV+gp120/alum-prime-boost组之间,以及在ALVAC-HIV+gp120/MF59-prime-boost组和ALVAC-HIV+gp120/MF59联合给药组之间,疫苗特异性IgA反应的发生率和净MFI均无明显差异。不足之处是每组样本量相对较小,且缺乏对更高剂量gp120的评估:结论:尽管MF59有望增强免疫反应,但明矾诱导的反应与MF59相似,这表明在ALVAC+gp120方案中选择这些佐剂可能并不重要:HVTN 107已在南非国家临床试验注册中心(DOH-27-0715-4894)和ClinicalTrials.gov(NCT03284710)注册。
{"title":"Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.","authors":"Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert","doi":"10.1371/journal.pmed.1004360","DOIUrl":"10.1371/journal.pmed.1004360","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Adjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen modified for the Southern African region. The RV144 trial of a recombinant canarypox vaccine vector expressing HIV env subtype B (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost adjuvanted with alum is the only trial to have shown modest HIV vaccine efficacy. Data generated after RV144 suggested that use of MF59 adjuvant might allow lower protein doses to be used while maintaining robust immune responses. We evaluated safety and immunogenicity of an HIV recombinant canarypox vaccine vector expressing HIV env subtype C (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost (gp120) adjuvanted with alum (ALVAC-HIV+gp120/alum) or MF59 (ALVAC-HIV+gp120/MF59) or unadjuvanted (ALVAC-HIV+gp120/no-adjuvant) and a regimen where ALVAC-HIV+gp120 adjuvanted with MF59 was used for the prime and boost (ALVAC-HIV+gp120/MF59 coadministration).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods and findings: &lt;/strong&gt;Between June 19, 2017 and June 14, 2018, 132 healthy adults without HIV in South Africa, Zimbabwe, and Mozambique were randomized to receive intramuscularly: (1) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/MF59 (months 3, 6, and 12), n = 36; (2) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/alum (months 3, 6, and 12), n = 36; (3) 4 doses of ALVAC-HIV+gp120/MF59 coadministered (months 0, 1, 6, and 12), n = 36; or (4) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120/no adjuvant (months 3, 6, and 12), n = 24. Primary outcomes were safety and occurrence and mean fluorescence intensity (MFI) of vaccine-induced gp120-specific IgG and IgA binding antibodies at month 6.5. All vaccinations were safe and well-tolerated; increased alanine aminotransferase was the most frequent related adverse event, occurring in 2 (1.5%) participants (1 severe, 1 mild). At month 6.5, vaccine-specific gp120 IgG binding antibodies were detected in 100% of vaccinees for all 4 vaccine groups. No significant differences were seen in the occurrence and net MFI of vaccine-specific IgA responses between the ALVAC-HIV+gp120/MF59-prime-boost and ALVAC-HIV+gp120/alum-prime-boost groups or between the ALVAC-HIV+gp120/MF59-prime-boost and ALVAC-HIV+gp120/MF59 coadministration groups. Limitations were the relatively small sample size per group and lack of evaluation of higher gp120 doses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Although MF59 was expected to enhance immune responses, alum induced similar responses to MF59, suggesting that the choice between these adjuvants may not be critical for the ALVAC+gp120 regimen.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/s","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":null,"pages":null},"PeriodicalIF":15.8,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PLoS Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1